These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 24720680)

  • 41. J&J buys antiviral firm Alios.
    Nat Biotechnol; 2014 Nov; 32(11):1073. PubMed ID: 25380426
    [No Abstract]   [Full Text] [Related]  

  • 42. Disparity in market prices for hepatitis C virus direct-acting drugs.
    Andrieux-Meyer I; Cohn J; de Araújo ES; Hamid SS
    Lancet Glob Health; 2015 Nov; 3(11):e676-7. PubMed ID: 26475012
    [No Abstract]   [Full Text] [Related]  

  • 43. NICE approval of new hepatitis drug could result in £700m bill for NHS.
    Hawkes N
    BMJ; 2015 Oct; 351():h5554. PubMed ID: 26491096
    [No Abstract]   [Full Text] [Related]  

  • 44. Sovaldi dilemma likely to get worse.
    Carroll J
    Manag Care; 2014 Sep; 23(9):9, 12. PubMed ID: 25282860
    [No Abstract]   [Full Text] [Related]  

  • 45. Pharmacology Focus: Hepatitis C: Remaining Challenges in the Treatment of Hepatitis C.
    Lemon M; Jesse S; Watchorn P
    S D Med; 2019 Sep; 72(9):424-425. PubMed ID: 31581378
    [No Abstract]   [Full Text] [Related]  

  • 46. The Treatment of Hepatitis C- An Introduction to the Use of New Medicines.
    Wörmann B
    Dtsch Arztebl Int; 2017 Jan; 114(1-02):9-10. PubMed ID: 28143634
    [No Abstract]   [Full Text] [Related]  

  • 47. Hepatitis C treatment in Guatemala: the struggle for access.
    Webster P
    Lancet; 2018 Jul; 392(10144):269-270. PubMed ID: 30064642
    [No Abstract]   [Full Text] [Related]  

  • 48. Deciding who should be treated for hepatitis C infection in a rapidly changing therapeutic landscape.
    Wiktor SZ
    Hepatology; 2015 Jul; 62(1):13-5. PubMed ID: 25820452
    [No Abstract]   [Full Text] [Related]  

  • 49. The Ethics, Cost, and Evidence Surrounding Current Pharmacological Treatment of Hepatitis C Virus Infection.
    O'Malley PA
    Clin Nurse Spec; 2017; 31(4):186-188. PubMed ID: 28594667
    [No Abstract]   [Full Text] [Related]  

  • 50. Market watch: The industry's biggest drug launches.
    Urquhart L
    Nat Rev Drug Discov; 2018 Nov; 17(12):855. PubMed ID: 30482955
    [No Abstract]   [Full Text] [Related]  

  • 51. [Treatment of hepatitis C: decisive therapeutic advances].
    Hartig-Lavie K; Bailly F; Lebossé F; Pagès-Ecochard M; Zoulim F
    Rev Prat; 2020 Feb; 70(2):e69-e70. PubMed ID: 32877153
    [No Abstract]   [Full Text] [Related]  

  • 52. Leaving no one behind: Towards equitable global elimination of hepatitis C.
    Dahl EH; Zahid H; Aslam K; Jafri W
    J Glob Health; 2020 Jun; 10(1):010308. PubMed ID: 32257136
    [No Abstract]   [Full Text] [Related]  

  • 53. Prisoners, hard hit by hepatitis C, decry lack of access to drugs.
    Willyard C
    Nat Med; 2012 Nov; 18(11):1594-5. PubMed ID: 23135494
    [No Abstract]   [Full Text] [Related]  

  • 54. Secrecy on cost of publicly funded hep C treatment.
    Webster P
    CMAJ; 2017 Apr; 189(16):E617-E618. PubMed ID: 28438961
    [No Abstract]   [Full Text] [Related]  

  • 55. Reducing the price of new hepatitis C drugs in the Tuscany region of Italy.
    Brunetto MR; De Luca A; Messori A; Zignego AL
    BMJ; 2015 Jun; 350():h3363. PubMed ID: 26108546
    [No Abstract]   [Full Text] [Related]  

  • 56. [Price of new drugs for hepatitis C: Try to understand the incomprehensible].
    Bergmann JF
    Presse Med; 2015 Sep; 44(9):877-80. PubMed ID: 26453430
    [No Abstract]   [Full Text] [Related]  

  • 57. Public health round-up.
    Bull World Health Organ; 2016 Apr; 94(4):237-8. PubMed ID: 27034514
    [No Abstract]   [Full Text] [Related]  

  • 58. [The paradox of fatty diet on protease inhibitors against C hepatitis].
    Vida Pérez L
    Gastroenterol Hepatol; 2013 Oct; 36(8):549-50. PubMed ID: 23809310
    [No Abstract]   [Full Text] [Related]  

  • 59. Reply.
    Fernández Carrillo C; Perelló C; Calleja JL
    Clin Gastroenterol Hepatol; 2017 May; 15(5):791. PubMed ID: 28163213
    [No Abstract]   [Full Text] [Related]  

  • 60. Authors' response to Letter to the Editor: 'Colombian experience in the management of hepatitis C'.
    Schroeder S; Pedrana A; Scott N; Hellard M
    Liver Int; 2020 Dec; 40(12):3142-3143. PubMed ID: 32875663
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.